**Pfizer Support to European and International Patient Organisations in 2017**

**Support to European organisations**

The below list contains information on the support Pfizer has provided to European-level patient organisations in 2017, and services contracted from them (e.g. speaker fees), and to national and global patient organisations for European-level work. It follows the standards set out in the EFPIA code of practice governing relationships between the pharmaceutical industry and patient associations. Note that many of these declarations have also been declared in the country in which an organisation is based, dependent on local guidelines.

<table>
<thead>
<tr>
<th>Organisation</th>
<th>Description</th>
<th>Funding</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Alzheimer Europe</strong></td>
<td>Alzheimer Europe is a non-governmental organisation aimed at raising awareness of all forms of dementia by creating a common European platform through co-ordination and co-operation between Alzheimer organizations throughout Europe. Alzheimer Europe is also a source of information on all aspects of dementia.</td>
<td>Pfizer provided €20,000 as sponsors of Alzheimer Europe’s corporate programme. This information is also declared on <a href="http://www.pfizer.be">www.pfizer.be</a>. Please be aware that the format may differ to follow Belgian transparency guidelines.</td>
</tr>
<tr>
<td><strong>AntiCoagulation Europe (ACE)</strong></td>
<td>ACE is a UK registered charity founded in the year 2000. ACE works with patients, healthcare professionals, NHS trusts, industry, governments, other charities and patient groups and a wide range of other organisations. Its aims are: the prevention of thrombosis; the provision of information, education and support; the promotion of independence - supporting people to take an active part in their own healthcare.</td>
<td>Pfizer Ltd on behalf of the BMS-Pfizer Alliance (an alliance between Bristol-Myers Squibb Pharmaceuticals Ltd and Pfizer Ltd) provided a consultancy fee of £450 to ACE. This figure is the total of Pfizer’s contribution via the Pfizer-BMS alliance, and is 50% of the total paid. This information is also declared on <a href="http://www.pfizer.co.uk">www.pfizer.co.uk</a>. Please be aware that the format may differ to follow UK transparency guidelines.</td>
</tr>
</tbody>
</table>
| **Europa Colon** | European umbrella organisation that works with 43 groups in 32 European countries and has been recognised as the voice of colorectal cancer patients in Europe. EuropaColon aims to unite patients, caregivers, healthcare professionals, politicians, the media and the public in the fight against digestive cancers. | }
<table>
<thead>
<tr>
<th>Amount</th>
<th>Description</th>
</tr>
</thead>
<tbody>
<tr>
<td>€25,000</td>
<td>Pfizer Inc provided a grant to support the 2017 Europa Colon Masterclass.</td>
</tr>
<tr>
<td>€500</td>
<td>Europa Colon received a consultancy fee of €500 paid by Hanover Communications.</td>
</tr>
</tbody>
</table>

This information is also declared on [www.pfizer.co.uk](http://www.pfizer.co.uk). Please be aware that the format may differ to follow UK transparency guidelines.

### Europa Donna

**Organisation Description**

Europa Donna, the European Breast Cancer Coalition, is an independent non-profit organisation founded in 1993, whose members are affiliated groups from countries across Europe. The Coalition works to raise awareness of breast cancer and to mobilise the support of European women in pressing for improved breast cancer education, appropriate screening, optimal treatment and care and increased funding for research. Europa Donna represents the interests of European women regarding breast cancer to local and national authorities, as well as to institutions of the EU. Europa Donna has 46 country members and its Head Office is located in Milan, Italy.

**Funding**

<table>
<thead>
<tr>
<th>Amount</th>
<th>Description</th>
</tr>
</thead>
<tbody>
<tr>
<td>€50,000</td>
<td>Pfizer Inc provided a contribution to support Europa Donna’s annual work plan 2017.</td>
</tr>
<tr>
<td>€25,000</td>
<td>Pfizer Inc provided a contribution to support Europa Donna’s mBC Annual Meeting.</td>
</tr>
</tbody>
</table>

This information is also declared on [www.pfizer.it](http://www.pfizer.it). Please be aware that the format may differ to follow Italian transparency guidelines.

### European Cancer Patient Coalition

**Organisation Description**

Established in 2003, the European Cancer Patient Coalition is the voice of the European cancer patient community, uniquely representing the interests of all cancer patient groups from the most common to the rarest forms of cancer.

**Funding**

<table>
<thead>
<tr>
<th>Amount</th>
<th>Description</th>
</tr>
</thead>
<tbody>
<tr>
<td>€15,000</td>
<td>Pfizer Inc provided support for the 2017 ECPC annual meeting.</td>
</tr>
<tr>
<td>€20,000</td>
<td>Pfizer Inc provided support for the preparation of ECPC’s white paper on cancer carers.</td>
</tr>
<tr>
<td>€500</td>
<td>ECPC received a consultancy fee of €500 paid by Hanover Communications.</td>
</tr>
</tbody>
</table>

This information is also declared on [www.pfizer.be](http://www.pfizer.be). Please be aware that the format may differ to follow Belgian transparency guidelines.

### European Federation of Chrohn’s and Ulcerative Colitis Associations (EFCCA)

**Organisation Description**

EFCCA is a European umbrella organisation representing 33 national patients’ associations. EFCCA aims to work to improve life for people with IBD and give them a louder voice and higher visibility across Europe and beyond.
This information is also declared on [www.pfizer.be](http://www.pfizer.be). Please be aware that the format may differ to follow Belgian transparency guidelines.

### European Federation of Neurological Associations (EFNA)

**Organisation Description**
The European Federation of Neurological Associations (EFNA) brings together European umbrella organisations of neurological patient advocacy groups, to work with other associations in the field of neurology, in what has been termed a 'Partnership for Progress'. EFNA engages in activities, which contribute to the advancement of neurology and related areas with a view to improving the quality of life of people living with neurological conditions, their families and carers.

**Funding**
Pfizer Inc provided a €75,000 policy-focused healthcare charitable contribution to support EFNA’s 2017 keynote policy projects

### European Haemophilia Consortium (EHC)

**Organisation Description**
The European Haemophilia Consortium (EHC) is a European patient group representing national member organisations from 43 countries in Europe including members in all 28 Member States. The EHC is working to reduce the burden of the disease on both the individual and on society. Its mission is to improve the quality of life of people with Haemophilia in Europe.

**Funding**
Pfizer Inc provided €60,000 funding to support the EHC Tenders and Procurement Workshop in Sofia, Bulgaria.

### European Huntington Association (EHA)

**Organisation Description**
The European Huntington Association (EHA) is an umbrella organization formed by Huntington’s disease (HD) associations all over Europe. EHA will share information and connect people through our unique cross border network. Together we will let our voice be heard and work for better care, treatment and research.

**Funding**
Pfizer Inc provided €20,000 to support EHA’s annual meeting.

**European Network of Gynaecological Oncology Patient Organisations (ENGAGE)**

**Organisation Description**
Established in 2012, the European Network of Gynaecological Cancer Advocacy Groups is a network of European patient advocacy groups established by European Society of Gynaecological Oncology representing all gynaecological cancers particularly (ovary, endometrial, cervix, vulva and rare cancers).

**Funding**
Pfizer Inc provided $35,000 to support the ENGAGE annual meeting 2017.

**European Parkinson's Disease Association (EPDA)**

**Organisation Description**
As the leading voice for Parkinson’s in Europe, EPDA provides information and resources to all Parkinson’s stakeholders, raises awareness of the disease’s complexities and impact, and advocates for concrete policy change that benefits the Parkinson’s community.

**Funding**
Pfizer Inc provided €25,000 as a gold corporate partnership.

This information is also declared on [www.pfizer.co.uk](http://www.pfizer.co.uk). Please be aware that the format may differ to follow UK transparency guidelines.

**European Patients' Forum (EPF)**

**Organisation Description**
The European Patients’ Forum (EPF) is the umbrella patients’ organisation at EU level. It brings together a broad range of leading European and national patients’ organisations in different disease areas. Representing over 150 million patients, the EPF is a key interlocutor with European institutions, and promotes patients’ rights, participation and involvement in EU healthcare developments.

**Funding**

<table>
<thead>
<tr>
<th>Amount</th>
<th>Description</th>
</tr>
</thead>
<tbody>
<tr>
<td>€30,000</td>
<td>Pfizer SA/NV provided a grant to support EPF’s annual work programme.</td>
</tr>
<tr>
<td>€25,000</td>
<td>Pfizer Inc provided a grant support to EFF’s Capacity Building Programme (payment initiated by Pfizer in 2016, received by EPF in 2017).</td>
</tr>
<tr>
<td>€6,250</td>
<td>Pfizer Inc provided a healthcare charitable contribution for journal access for EUPATI fellows.</td>
</tr>
</tbody>
</table>

This information is also declared on [www.pfizer.be](http://www.pfizer.be). Please be aware that the format may differ to follow Belgian & Luxembourgish transparency guidelines.

**EURORDIS (European Organisation for Rare Diseases)**

**Organisation Description**
EURORDIS is a patient-driven alliance of patient organisations and individuals active in the field of rare diseases. EURORDIS’ mission is to build a strong pan-European community of patient organisations and people living with rare diseases, to be their voice at the European level, and -
directly or indirectly - to fight against the impact of rare diseases on their lives.

**Funding**
Pfizer Inc provided €130,000 to support the EURORDIS international initiative and capacity building.

This information is also declared on [www.pfizer.fr](http://www.pfizer.fr). Please be aware that the format may differ to follow French transparency rules.

**International Diabetes Federation Europe (IDF-Europe)**

**Organisation Description**
As the only European advocate for people with diabetes and their healthcare providers, the International Diabetes Federation European Region works together with its member associations and other diabetes stakeholders to enhance the lives of people with diabetes. Many IDF member associations are made up of people with diabetes and health care professionals. The mission of the International Diabetes Federation is to promote diabetes care, prevention and a cure worldwide.

**Funding**
Pfizer Ltd provided a policy-focused healthcare contribution of €27,000 for the IDF Europe Corporate Partnership.

This information is also declared on [www.pfizer.be](http://www.pfizer.be). Please be aware that the format may differ to follow Belgian transparency guidelines.

**Lung Cancer Europe (LuCE)**

**Organisation Description**
Lung Cancer Europe is a non-governmental organisation which was established in 2013 to provide a voice for lung cancer patients and their families at a European level. Through its member organisations (which are lung cancer organisations with a patient focus), LuCE reflects patients’ and their carers’ and families’ unique and direct experience and expertise in healthcare.

**Funding**
Pfizer Pharma GmbH provided €25,000 to support LuCE’s goals and represent the patient’s voice at the EU level through 2017 CARE program: C create awareness of lung cancer; A access to the best possible treatment; R reduce mortality through early detection; E equality of care throughout Europe.

**Lymphoma Coalition Europe**

**Organisation Description**
The Lymphoma Coalition Europe (LCE) is the European branch of the Lymphoma Coalition (LC). It was created in 2015 to focus on issues of regional interest and to contribute to the implementation of LC mission and activities in Europe and in Israel.

**Funding**
Pfizer Inc provided €25,000 to support the Lymphoma Coalition Europe annual meeting.

This information is also declared on [www.pfizer.fr](http://www.pfizer.fr). Please be aware that the format may differ to follow French transparency rules.
### Meningitis Research Foundation

**Organisation Description**
Meningitis Research Foundation is a leading UK and international charity that brings together people and expertise to defeat meningitis and septicaemia wherever it exists.

**Funding**

<table>
<thead>
<tr>
<th>Amount</th>
<th>Description</th>
</tr>
</thead>
<tbody>
<tr>
<td>£30,000</td>
<td>Pfizer Ltd supported an educational/scientific meeting entitled '11th International Conference'.</td>
</tr>
<tr>
<td>£39,811</td>
<td>Pfizer Ltd provided a charitable donation to support 'Piece of Mind' research into consumer perspectives on vaccination.</td>
</tr>
<tr>
<td>£14,327</td>
<td>Pfizer International Operations commissioned consultancy services from MRF to support Pfizer in organising a meeting on vaccines programmes in the EU.</td>
</tr>
<tr>
<td>£1,725</td>
<td>Pfizer International Operations paid a consultancy fee for MRF to provide an expert speaker for a symposium at the ESPID congress.</td>
</tr>
<tr>
<td>£600</td>
<td>Pfizer International Operations paid the registration fees for the MRF speaker who presented at a symposium at the ESPID congress.</td>
</tr>
</tbody>
</table>

This information is also declared on [www.pfizer.co.uk](http://www.pfizer.co.uk). Please be aware that the format may differ to follow UK transparency guidelines.

### Pain Alliance Europe (PAE)

**Organisation Description**
PAE is an NGO umbrella organization of national associations which are all committed to improving the quality of life of people with chronic pain.

**Funding**
Pfizer Inc provided a policy-focused healthcare charitable contribution of €22,500 to support PAE’s policy activities in 2017.

This information is also declared on [www.pfizer.be](http://www.pfizer.be). Please be aware that the format may differ to follow Belgian transparency guidelines.

### Pulmonary Hypertension Association Europe (PHA Europe)

**Organisation Description**
The mission of Pulmonary Hypertension Association (Europe) is to find ways to prevent and cure pulmonary hypertension, and to provide hope for the pulmonary hypertension community through support, education, advocacy and awareness.

**Funding**
Pfizer Inc provided a policy-focused healthcare charitable contribution of €25,000 to support PHA Europe’s 2017 policy advocacy activities.

### Sarcoma Patients EuroNet (SPAEN)

**Organisation Description**
Established in 2009, Sarcoma Patients EuroNet e.V./Assoc. (SPAEN) is a collaborative association based in Germany, which brings together European advocacy and support groups working...
together with patients who have some of the rarest cancers. Acting in partnership with clinical experts, scientific researchers and other stakeholders SPAEN is working to improve the treatment and care of sarcoma patients in Europe through improving information and support, and by increasing the awareness of sarcoma in the medical landscape and amongst the general public.

**Funding**

<table>
<thead>
<tr>
<th>Amount</th>
<th>Description</th>
</tr>
</thead>
<tbody>
<tr>
<td>$35,000</td>
<td>Pfizer Inc supported the 2018 GIST/New Horizons conference.</td>
</tr>
<tr>
<td>€13,750</td>
<td>Pfizer Inc provided SPAEN annual sponsorship.</td>
</tr>
</tbody>
</table>

**Stroke Alliance for Europe (SAFE)**

**Organisation Description**
SAFE is a non-profit-making organisation that represents a range of patient groups from across Europe whose mutual goal is to drive stroke prevention up the European political agenda and prevent the incidence of stroke through education.

**Funding**
Pfizer Ltd on behalf of the BMS-Pfizer Alliance (an alliance between Bristol-Myers Squibb Pharmaceuticals Ltd and Pfizer Ltd) provided a contribution of €25,000 to the development of the Stroke Action Plan for Europe, and research into the economic impact of stroke. This figure is the total of Pfizer’s contribution via the Pfizer-BMS Alliance, and is 50% of the total paid.

This information is also declared on [www.pfizer.be](http://www.pfizer.be). Please be aware that the format may differ to follow Belgian transparency guidelines.

**Youth Cancer Europe**

**Organisation Description**
Youth Cancer Europe is a foundation that incorporates youth cancer networks across Europe.

**Funding**
Pfizer Inc provided €30,000 to support Youth Cancer Europe’s 2017 annual meeting and policy advocacy.
Support to global organisations based in Europe

The below list contains information on the support Pfizer has provided to global patient organisations in 2017 based in Europe.

<table>
<thead>
<tr>
<th>Organisation Description</th>
<th>Funding</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Confederation of Meningitis Organisations (COMO)</strong></td>
<td>£83,000 Pfizer Inc supported an adolescent policy prioritisation survey.</td>
</tr>
<tr>
<td></td>
<td>£34,962 Pfizer Inc made a charitable donation to support CoMO’s program 'Advancing Lifecourse Immunisation as a European Priority'.</td>
</tr>
<tr>
<td></td>
<td>£2,318 Pfizer Inc paid a consultancy fee relating to the Advancing Adolescent Health Spring Forum.</td>
</tr>
</tbody>
</table>

This information is also declared on [www.pfizer.co.uk](http://www.pfizer.co.uk). Please be aware that the format may differ to follow UK transparency guidelines.

<table>
<thead>
<tr>
<th><strong>International Alliance of Patient Organisations (IAPO)</strong></th>
<th>Funding</th>
</tr>
</thead>
<tbody>
<tr>
<td>IAPO is a unique global alliance representing patients of all nationalities across all disease areas and promoting patient-centred healthcare around the world.</td>
<td>£38,745 Pfizer Inc provided annual membership fees.</td>
</tr>
<tr>
<td></td>
<td>£1,472 Pfizer Pharma GmbH provided an honorarium for speaking at a patient advocacy conference.</td>
</tr>
</tbody>
</table>

This information is also declared on [www.pfizer.co.uk](http://www.pfizer.co.uk). Please be aware that the format may differ to follow UK transparency guidelines.

<table>
<thead>
<tr>
<th><strong>International Brain Tumour Alliance</strong></th>
<th>Funding</th>
</tr>
</thead>
<tbody>
<tr>
<td>The International Brain Tumour Alliance (IBTA) is a unique global network for brain tumour patient and carer groups around the world. We work alongside, and represent, members of our community - including researchers, scientists, clinicians, nurses and allied healthcare professionals - to engage in advocacy, to raise awareness and to share information.</td>
<td>Pfizer Inc provided £10,000 to support the IBTA annual work programme.</td>
</tr>
</tbody>
</table>

This information is also declared on [www.pfizer.co.uk](http://www.pfizer.co.uk). Please be aware that the format may differ to follow UK transparency guidelines.

<table>
<thead>
<tr>
<th><strong>International Conference on Rare Diseases &amp; Orphan Drugs (ICORD)</strong></th>
<th>Funding</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td></td>
</tr>
</tbody>
</table>
Organisation Description
ICORD is an International Society for all individuals actively involved in rare diseases and/or orphan drugs, including health care, research, academic, industry, patient organisations, regulatory authorities, health authorities, and public policy professionals. The mission of ICORD is to improve the welfare of patients with rare diseases and their families world-wide through better knowledge, research, care, information, education and awareness.

Funding
Pfizer Inc provided $12,500 to support the ICORD annual meeting in Beijing.

International Federation of Psoriasis Organisations (IFPA)

Organisation Description
IFPA is a non-profit organization made up of psoriasis associations from around the world. IFPA unites psoriasis associations so that their global campaign for improved medical care, greater public understanding and increased research will improve the lives of people who live with psoriasis and psoriatic arthritis and explore the challenges psoriasis presents to the international psoriasis community. IFPA is based in Sweden.

Funding
Pfizer Inc provided €65,000 to support IFPA’s annual work programme.

International Kidney Cancer Coalition (IKCC)

Organisation Description
IKCC is an independent and democratic network of patient support and advocacy organizations established with the mission of improving the quality of life of patients and their families living with kidney cancer. IKCC provides information, support and assistance to national kidney cancer organizations.

Funding
<table>
<thead>
<tr>
<th>Amount</th>
<th>Description</th>
</tr>
</thead>
<tbody>
<tr>
<td>$50,000</td>
<td>Pfizer Inc provided support to Kidney Cancer Awareness Day and advocacy strategic planning.</td>
</tr>
<tr>
<td>$55,000</td>
<td>Pfizer Inc contributed to 2017 Annual Sustaining Partners Membership.</td>
</tr>
<tr>
<td>€35,000</td>
<td>Pfizer Inc supported the kidney cancer patient survey</td>
</tr>
</tbody>
</table>

International Patient Organisation for Primary Immunodeficiencies (IPOPI)

Organisation Description
IPOPI is the association of national patient organisations dedicated to improving awareness, access to early diagnosis and optimal treatments for primary immunodeficiency (PID) patients worldwide. Established in 1992, IPOPI works as the global advocate for the PID patient community in cooperation with its national member organisations and key PID stakeholders.

Funding
Pfizer Inc provided €35,000 to support IPOPI corporate partnership at the Silver level.

This information is also declared on [www.pfizer.co.uk](http://www.pfizer.co.uk). Please be aware that the format may differ to follow Belgian transparency guidelines.

Leukemia Patient Advocates Foundation
**Organisation Description**
The Leukemia Patient Advocates Foundation is a patient-led non-profit foundation in Switzerland. Its mission is to improve the lives & survival of patients affected by Leukemia. It is a platform for discussions & best practice sharing to Leukemia patient groups worldwide. The foundation collaborates with all stakeholders involved in research, policy, treatment and care. It also acts as a platform for patient organisations – concentrating on educating, connecting and supporting patient group leaders.

**Funding**

<table>
<thead>
<tr>
<th>Amount</th>
<th>Description</th>
</tr>
</thead>
<tbody>
<tr>
<td>€50,000</td>
<td>Pfizer Inc provided support to the CML Horizons 2018 meeting.</td>
</tr>
<tr>
<td>€75,000</td>
<td>Pfizer Inc provided support to the Acute Leukemia Advocacy Network.</td>
</tr>
<tr>
<td>€6,000</td>
<td>Pfizer Inc provided support to the ALAN meeting at the European Hematology Association congress.</td>
</tr>
</tbody>
</table>

**World Alliance of Pituitary Organisations**

**Organisation Description**
The World Alliance of Pituitary Organizations (WAPO) is a self-governed non-profit organization created in order to unite the international pituitary patient community to push for optimal treatment and care for all patients with pituitary and related conditions worldwide. The goal of our organization is to share information, work together and support all pituitary patients’ advocates all around the world.

**Funding**
Pfizer Inc provided €25,000 support for the WAPO annual congress.
Appendix: Funding to organisations engaged in some work with patients.

Pfizer provides funding to a number of organisations that are not patient organisations, but which have patient organisation membership or are otherwise relevant to patients. As such, they are listed here for the sake of transparency.

**European Alliance for Personalised Medicine (EAPM):** Founded in 2012, The European Alliance for Personalised Medicine (EAPM) brings together Europe’s leading healthcare experts, healthcare organisations and institutions, and patient advocates to improve patient care by accelerating the development, delivery and uptake of personalised healthcare including personalised medicine and diagnostics. EAPM is based in Belgium. In 2017, Pfizer Inc. paid €10,000 for EAPM health congress sponsorship.

**European Brain Council (EBC):** The European Brain Council (EBC) is a coordinating council formed by European organisations in neurology, neurosurgery, psychiatry, basic brain research (neuroscience), as well as patient organisations and companies from within the pharma and biotech industries. It represents a vast network of patients, doctors and scientists, and these stakeholders along with its industrial partners make it eminently suited to work in close partnership with the European Parliament and Commission, national governments as well as other policy making bodies. EBC is based in Belgium. In 2017 Pfizer Ltd provided EBC with €20,000 as an annual membership fee.

**Eurocarers:** Eurocarers is the European network representing informal carers and their organisations, irrespective of the particular age or health need of the person they are caring for. In 2017, Pfizer Inc provided €23,000 to support the development of an information toolkit for carers of cancer patients.

**European Society for Medical Oncology (ESMO):** ESMO is the leading European professional organisation for medical oncology. Comprising more than 15,000 oncology professionals from over 130 countries, ESMO is the society of reference for oncology education and information. ESMO is based in Switzerland. In 2017, Pfizer Inc. provided €15,000 to support the Patient Advocacy Track at the 2016 ESMO Congress.

**European Network for Smoking and Tobacco Prevention (ENSP):** ENSP has more than 60 member organisations from across Europe. It aims to create greater coherence among smoking prevention activities and to promote comprehensive tobacco control policies, at both national and European levels, in order to prevent ill health and early death from tobacco-related causes. In 2017, Pfizer Inc provided ENSP with a policy-focused healthcare charitable contribution of €15,000.